OncoPep is developing PVX-410, an investigational cancer vaccine designed to stop disease progression in multiple myeloma. In addition to smoldering multiple myeloma (SMM), our investigational peptide portfolio more broadly targets multiple myeloma, triple negative breast cancer (TNBC) and several solid cancer tumors (breast, colon, pancreatic, prostate).
http://www.oncopep.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
0.7 seconds
OncoPep
Doris Peterkin
520 Bo●●●●●●Street
Nort●●●●over , MA, 01845
US
View this contact
OncoPep
Doris Peterkin
520 Bo●●●●●●Street
Nort●●●●over , MA, 01845
US
View this contact
OncoPep
Doris Peterkin
520 Bo●●●●●●Street
Nort●●●●over , MA, 01845
US
View this contact
BUY YOUR DOMAIN
15
YEARS
6
MONTHS
25
DAYS
DOMAIN.COM, LLC
WHOIS : whois.domain.com
REFERRED : http://www.domain.com
PAGES IN
THIS WEBSITE
5
SSL
EXTERNAL LINKS
0
SITE IP
198.185.159.144
LOAD TIME
0.703 sec
SCORE
6.2
OncoPep | oncopep.com Reviews
https://oncopep.com
OncoPep is developing PVX-410, an investigational cancer vaccine designed to stop disease progression in multiple myeloma. In addition to smoldering multiple myeloma (SMM), our investigational peptide portfolio more broadly targets multiple myeloma, triple negative breast cancer (TNBC) and several solid cancer tumors (breast, colon, pancreatic, prostate).
oncopep.com
Sitemap - OncoPep
https://www.oncopep.com/help/sitemap.php
OncoPep 2014 Privacy Policy.
Therapeutic Cancer Vaccines - Cancer Vaccine Program - OncoPep
https://www.oncopep.com/cancer-vaccine-program/therapeutic-cancer-vaccines.php
Therapeutic vaccines are based on the premise that cancer develops as a result of the immune system not mounting an effective immune response against cancer cells, and that the immune system can be "trained" to recognize and attack cancer cells, halting the growth of established tumors. Therapeutic vaccines are used much differently than traditional preventative vaccines, as they are administered to treat existing disease rather than to prevent disease. OncoPep's lead therapeutic cancer vaccine, PVX-410.
Overview - About Us - OncoPep
https://www.oncopep.com/about-us/about-us-overview.php
OncoPep’s lead program, PVX-410. Is a multi-peptide therapeutic cancer vaccine that is designed to target specific antigens found on the surface of multiple myeloma (MM) cancer cells. MM is a cancer of the plasma cells for which there is currently no cure. The initial clinical target is smoldering multiple myeloma. A precursor disease to MM for which there are no approved treatments. PVX-410 was granted orphan drug designation from the U.S. Food and Drug Administration in 2013. OncoPep 2014 Privacy Policy.
OncoPep
https://www.oncopep.com/index.html
OncoPep is developing targeted immunotherapeutics to prevent the progression of cancer, prolong survival and restore the quality of life of patients. OncoPep's lead program is a therapeutic cancer vaccine for use in treating smoldering multiple myeloma. OncoPep Presents Updated Results of a Phase 1/2a Clinical Trial with Multi-Peptide Vaccine to Treat Smouldering Multiple Myeloma. OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial.
Overview - Multiple Myeloma - OncoPep
https://www.oncopep.com/multiple-myeloma/about-multiple-myeloma.php
Multiple myeloma (MM) is a debilitating type of hematologic (or blood) cancer that affects plasma cells. It is the second most common blood cancer, accounting for 13% of all hematologic cancers and 1% of all cancer deaths. The American Cancer Society estimated that approximately 22,350 new cases of MM were diagnosed in 2013. OncoPep 2014 Privacy Policy.
TOTAL PAGES IN THIS WEBSITE
5
Hebergement, enregistrement de nom de domaine et services internet par 1&1 Internet
CE NOM DE DOMAINE VIENT D'ÊTRE ENREGISTRÉ POUR L'UN DE NOS CLIENTS ! Avez-vous besoin, vous aussi, d'une VRAIE solution d'hébergement VRAIMENT accessible? Vous propose les solutions les moins chères du Net pour réaliser votre site web en toute simplicité, que vous soyez débutant ou expérimenté. Des solutions d'hébergement complètes. Une large gamme de logiciels offerts. Un espace de configuration intuitif. Une assistance technique efficace. Aucun engagement de durée. Garantie satisfait ou remboursé.
OncoPDA – hematology and oncology web apps
Darr; Skip to Main Content. The future is mobile and the future is multi-platform. With that, OncoPDA has been revamped, focusing on mobile medical web apps. The advantage of these apps are that they are platform independent and can run on iOS, Android and even your desktop browser. These are apps based on HTML5 technology and can run offline like a regular app on your smartphone or iPad provided you save it as a shortcut on your Home screen. Tips on using this site. Check out the apps from our General.
Oncoped | Oncología pediátrica
044) 55 5402 0955. Dr Carlos A Leal. Dr Carlos A. Leal. Diagnóstico, tratamiento, evaluación y seguimiento. Diagnóstico, tratamiento, evaluación y seguimiento. Acerca del Dr. Carlos A. Leal. 044) 55 5402 0955. Viaducto Río Becerra 97-desp 311 Colonia Nápoles, Ciudad de Mèxico, México, C.P. 03810. Diseño de página por Neoweb.
Tratamiento infantil de enfermedades oncologicas y hematologicas
Organización de la Unidad. Trasplante autólogo de médula. El niño y su familia. Oncología Pediátrica 902107469 Hematología Pediátrica 902089800. 34 639 713 145. Unidad de Hematología y Oncología Pediátrica. La unidad de Hematología y Oncología Pediátrica del Grupo HM, y que dirige la. Con la Dra. Marta Villa. Como jefe clínico, está ubicada en el Hospital Universitario HM Monteprincipe. Y con HM Hospitales. Unidad de Hematología y Oncopediatria. Cómo lo estamos haciendo. El próximo 29 de noviembre a las ...
الرئيسية - برنامج محمد بن راشد للتعلم الذكي
برنامج محمد بن راشد للتعلم الذكي. برنامج التعلم الذكي هي مبادرة أطلقها الشيخ محمد بن راشدآل مكتوم في أبريل 2012، والتي تهدف إلى تطوير بيئةلدعم إصلاح التعليم في دولة الإمارات العربية المتحدة. وهي موجهة لجميع المدارس الحكوميةالتابعة لوزارة التربية والتعليم من خلال خطة تمهيديةلفترة خمس سنوات. تم تطوير العام الماضي 450 محتوى تعليمي الكتروني وفقا للمنهج الدراسي للصف السابع. المشروع الحالي يهدف إلى تطوير 870 محتوى تعليمي الكتروني للصف الثامن.
OncoPep
FOR THE TREATMENT OF CANCER. OncoPep is developing PVX-410,. An investigational cancer vaccine designed to stop disease progression in multiple myeloma. In addition to smoldering multiple myeloma (SMM), our investigational peptide portfolio more broadly targets multiple myeloma, triple negative breast cancer (TNBC) and several solid cancer tumors (breast, colon, pancreatic, prostate). Our initial clinical focus is to halt disease progression in SMM and TNBC. Learn More ABOUT SMM and MM. 520 Boston Street,.
Oncopeptides
Investors and media contact. Annual General Meeting 2018. The Board of Directors. Work of the Board of Directors. CEO Jakob Lindberg on Oncopeptides and Ygalo. Oncopeptides is a clinical development pharmaceutical company focused on bringing anti-cancer research as treatments for the benefit of patients. Was published on February 22, 2018. Read the full report. April 12, 2018. First patient starts treatment in Oncopeptides’ Phase I / II ANCHOR study with Ygalo. March 29, 2018. March 26, 2018. May 17, 2018.
ONCOPET - Oncologia Veterinária
Eacute; esse o principal objetivo do Oncopet, nossa missão é ajudar os proprietários de cães e gatos a darem qualidade de vida aos pacientes Oncológicos. O Oncopet é formado por uma equipe de profissionais especializados na área de Oncologia Veterinária que fazem atendimento em diversas Clínicas e Hospitais no Estado de São Paulo. Oncopet - Todos os Direitos Reservados - www.oncopet.com.br. Powered by Interativa - www.grupointerativa.com.br - Tel.:(12) 3633.8202.
保険に見直しはつきものだから定期的に相談をする
Posted by oncopetdiagnostics.com. On 3月 - 5 - 2014. 一般的に、保険というのは 難しいもの 勧誘がしつこいもの のようなイメージがあります。 なぜ、一度加入した保険を見直さないといけないのでしょう その理由を一言で言うと、 状況が変わるから です。 自転車保険に入っておけば安心です ここをチェックしてみてください ネットde保険 さいくる. Designed by: Quality Hosting. Contributions by: Vertalen Nederlands Frans.
UNAC
2012 Oncopets - UNAC. Todos los Derechos Reservados. Creado por AMS media. Tel.: 83-56-95-99, 83-78-21-88 y 41-96.
